Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Safety and efficacy of sacubitril/valsartan in patient with heart failure
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: RAY, Chin (Chang Gung Memorial Hospital, Linkou, Taiwan, Department of Pharmacy)
- Co-author(s): Chin-Ying Ray
BackgroundPatients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization and high mortality rate within 5 years.According to the PARADIGM-HF study, sacubitril/valsartan (Entresto) reduce cardiovascular risk by 20%. However, clinicians are still worried whether this medicine will cause.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019